首页> 外国专利> Use of a hemoglobin oxygen carrier for the treatment of cancerous tissue and the preparation of a pharmaceutical composition for preventing recurrence and metastasis of cancerous tumors

Use of a hemoglobin oxygen carrier for the treatment of cancerous tissue and the preparation of a pharmaceutical composition for preventing recurrence and metastasis of cancerous tumors

机译:血红蛋白氧载体在治疗癌性组织中的用途以及制备用于预防癌性肿瘤复发和转移的药物组合物的用途

摘要

The present invention provides a pharmaceutical composition containing a hemoglobin-based oxygen carrier for treating cancer, preventing recurrence and metastasis of cancerous tumor. The composition can be used alone or in combination with at least one chemotherapeutic agent such as 5FU, Bortezomib, doxorubicin, cisplatin, or any combination thereof. The hemoglobin-based oxygen carrier in the composition is capable of targeting a surface receptor expressed on cancerous cells and facilitating the uptake of both hemoglobin-based oxygen carrier and the chemotherapeutic agent by the cancerous cells via a receptor-mediated mechanism. The hemoglobin-based oxygen carrier inhibits the expression of hypoxic response elements such as HIF1, VEGF, ET1, VHL, etc. The pharmaceutical composition of the present invention is also useful for inducing the apoptosis or cell death of a type of self-renewing and tumor-initiating cells called cancer stem cells which are located in the hypoxic niche of a cancerous tumor.
机译:本发明提供了含有基于血红蛋白的氧载体的药物组合物,用于治疗癌症,预防癌性肿瘤的复发和转移。该组合物可以单独使用或与至少一种化学治疗剂如5FU,硼替佐米,阿霉素,顺铂或其任何组合结合使用。组合物中基于血红蛋白的氧载体能够靶向在癌细胞上表达的表面受体,并通过受体介导的机制促进癌细胞对基于血红蛋白的氧载体和化学治疗剂的摄取。基于血红蛋白的氧载体抑制缺氧反应元件如HIF1,VEGF,ET1,VHL等的表达。本发明的药物组合物也可用于诱导细胞凋亡或细胞自我更新和死亡的类型。肿瘤起始细胞称为癌干细胞,位于癌性肿瘤的低氧环境中。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号